Cormorant Asset Management, LP has filed its 13F form on August 14, 2024 for Q2 2024 where it was disclosed a total value porftolio of $1.3 Billion distributed in 49 stocks.
Among their holdings, we can observe that their the top five positions include companies like: Moon Lake Immunotherapeutics with a value of $373M, Arcellx, Inc. with a value of $84.2M, Vaxcyte, Inc. with a value of $83.1M, Longboard Pharmaceuticals, Inc. with a value of $75.4M, and Eye Point Pharmaceuticals, Inc. with a value of $72.4M.
Examining the 13F form we can see an decrease of $438M in the current position value, from $1.74B to 1.3B.
Cormorant Asset Management, LP is based out at Boston, MA
Below you can find more details about Cormorant Asset Management, LP portfolio as well as his latest detailed transactions.